Cat II · Managed by InvAscent
India's Leading Life Sciences Private Equity Firm
Private equity, private credit and real-estate funds that don't employ leverage except for operating needs. The largest AIF category.
India Life Sciences Fund IV Domestic (IN/AIF2/23-24/1403) is a SEBI-registered Category II AIF managed by Invascent ILSF Manager LLP, the investment management entity of InvAscent — India's leading life sciences-focused private equity firm. This domestic AIF is the India-domiciled companion vehicle to the offshore fund (India Life Sciences Fund IV / ILSF IV). ILSF IV has a total size of USD 304 million (PitchBook) with IFC (International Finance Corporation) as a key LP (USD investment confirmed from IFC disclosures; latest commitment May 2025). InvAscent has raised ~USD 500 million across four funds and deployed capital in 35+ companies. The fund is at its 20th anniversary year (2026 logo). The manager address is Plot No. 1174-A, Road No. 36 (also listed as Road No. 56 per LEI), Jubilee Hills, Hyderabad – 500033. Fund IV is in active deployment: 8 investments including Fleming Laboratories (INR 1,100M, API pharma), Geri Care Health Services (INR 1,100M, eldercare), ABI Health Technologies (USD 10M, health-tech SaaS), and Maiva Pharma.
Hariharnath Buggana
Chairman & Managing Director, InvAscent
Hariharnath (Hari) Buggana is the Chairman and Managing Director of InvAscent and the designated investment professional for India Life Sciences Fund IV per IFC's project documentation. He holds an MBA from J.L. Kellogg Graduate School of Management, Northwestern University, an MS in Chemical Engineering from Illinois Institute of Technology, and a BE in Chemical Engineering from University of Poona.
Nithya Govind
Managing Director
Nithya Govind is Managing Director at InvAscent and the SEBI-designated contact person for India Life Sciences Fund IV Domestic. She leads investment execution in the pharma and API space. She quoted on the Fleming Laboratories investment: 'with great chemistry skills and excellent operational capabilities, Fleming has established itself as one of the fastest growing API companies.' She also led the Geri Care Health Services eldercare investment.
T.P. Devarajan
Partner / Investment Team, InvAscent
T.P. Devarajan is a Partner at InvAscent contributing to investment execution and portfolio management for the ILSF fund family.
Anil Jagirdar
Director, InvAscent
Anil Jagirdar is a Director at InvAscent. He led the ABI Health Technologies investment (ILSF IV), stating: 'Indian Health-Tech is always seen as a challenging space but we see this changing rapidly with increasing adoption of tech.' He holds an MBA from IIM Shillong and a BTech in Biotechnology from Osmania University.
Paritosh Nayak
Investment Team, InvAscent
Paritosh Nayak has 13+ years in private equity and healthcare. Prior to InvAscent, he worked at Dr. Reddy's Laboratories (6 years), Jubilant Life Sciences (2 years), and Mylan India. He holds a PGP from ISB Hyderabad and Master & Bachelor of Pharmacy from Jadavpur University.
No insights published yet.
Investments in AIFs carry market and credit risk including possible loss of capital. Past performance does not indicate future returns. Information shown is sourced from the issuer's PPM and SEBI filings — confirm against the latest PPM before committing. Wisefolio is an information platform; it is not registered with SEBI as an investment adviser, portfolio manager, or distributor. By using this page you accept our terms and privacy policy, including the self-attestation that you are eligible to view AIF marketing material under SEBI rules.
Henal Vora
Investment Team, InvAscent
Henal Vora previously served as VP at Tata Capital Healthcare Fund (2 investments, portfolio management), led M&A for Piramal Pharma's critical care business, and spent 5 years at KPMG investment banking. He holds an MBA from IIM Indore and BTech (CS) from IIT Kharagpur.
Ankit Pawar
Investment Team, InvAscent
Ankit Pawar has 11+ years in PE, investment banking, and healthcare. Previously an Investment Banking Associate at Torreya Partners (global healthcare IB, 6 years) and Corporate Strategy Manager at Nectar Lifesciences. Holds MBA from University Business School, Panjab University, and BTech in Biotechnology from Thapar University.
Ashwini Mogilisetty
Investment Team, InvAscent
Ashwini Mogilisetty has 6+ years in PE and investment banking. Previously an Investment Analyst at Eversource Capital (2 years) and in investment banking prior to that.
Hemant Ajmera
Complaint Redressal Appellate Officer
Hemant Ajmera has 12+ years in financial services and corporate finance. Previously VP (Finance) at Equirus Securities (fund administration, accounting, investor reporting), and 6 years at GVFL (VC fund) and SBICap Trustee in financial controllership. Holds BCom from Mohanlal Sukhadiya University, CA and CS designations.
Dr. Jeevak Gupta
Managing Director
Dr.
Bhavesh Sonesara
Complaint Redressal Officer
Henal Agrawal
May Philips
Neha Pereira
Dr. Sankalp Anand
Dr.
Shivam Rajoriya
Shweta Agrawal
Venkata Sainath Dadi
See every PMS strategy and AIF from InvAscent.